Johnson & Johnson on Tuesday reported fourth-quarter revenues and income that beat Wall Street’s expectations. The business also said it would launch crucial information on its coronavirus vaccine “soon.”
Here’s how J&J did compared to what Wall Street expected, according to typical price quotes assembled by Refinitiv:
- Adjusted EPS: $1.86 per share versus $1.82 expected.
- Income: $2248 billion versus $2167 billion anticipated.
” I’m exceptionally proud of our Johnson & Johnson teams worldwide for exceeding and beyond to fulfill stakeholder needs,” CEO Alex Gorsky said in a press release. “We continue to advance our COVID-19 vaccine candidate and eagerly anticipate sharing information from our Phase 3 research study quickly.”
J&J’s share price was essentially flat in premarket trading following the report.
J&J’s pharmaceutical company, which is working on a coronavirus vaccine, created $12 The business’s customer unit, which makes products such as Listerine, generated $3.6 billion in earnings, up 1.4%from a year earlier.
The business forecasted an adjusted revenue for 2021 of $9.40 to $9.60 per share and sales varying from $905 billion to $917 billion.
J&J is anticipated to launch information from its phase three trial testing its Covid-19 vaccine as early as today.
U.S. authorities and Wall Street experts are eagerly expecting the federal permission of J&J’s vaccine, which could take place as early as next month. Unlike Pfizer’s and Moderna’s authorized vaccines, which need two dosages provided about 3 to four weeks apart, J&J’s needs just one dosage. That indicates patients will not have to return for another dosage, streamlining logistics for health-care suppliers.
J&J Chief Financial Officer Joseph Wolk told CNBC on Tuesday the company anticipates the stage 3 trial information to be “robust.” He stated it’s possible there might be distinctions in results for individuals tested in places like South Africa, where there is a new, highly contagious strain of the virus.
Moderna stated Monday it is working on a booster shot to defend against the stress discovered in South Africa after it found its existing vaccine seemed less reliable.
” It’s going to be really inclusive in regards to having particular ethnicities [such as] Blacks, Hispanics and the senior,” Wolk said on “ Squawk Box” “Since it’s so varied because of the geographic representation that might provide a great deal of insights.”
No comments:
Post a Comment